Earnings Per Share (GAAP)
$-0.55
vs $-0.34 est. (wider loss, 63.4%)
Revenue
$2.8M
vs $5.3M est.
Analyst support remains intact. Despite the wider-than-expected loss, the Street maintains unanimous bullish conviction with 8 Buy or Strong Buy ratings and zero Hold or Sell recommendations. This suggests analysts view the quarter’s shortfall as a timing issue rather than a fundamental setback. The stock trades at $16.02 with a market cap of $1.25 billion.
What to Watch: Management commentary on pipeline progress and partnership milestones will be critical to assess whether the revenue shortfall reflects delayed timing or structural headwinds. Clinical trial readouts and regulatory updates for the company’s molecular glue degrader platform will drive the next rerating catalyst.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.